Note 5 - Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2025

Notes Tables

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	Fair Value			Fair value measurement using
	March 31,
(in thousands)	2025			Level 1		Level 2		Level 3
Assets:
Money market funds	$	604		$	604	$	-	$	-
Total Assets	$	604		$	604	$	-	$	-
Liabilities:
Senior secured notes payable	$	(374	)	$	-	$	-	$	(374	)
Common stock warrant liability		(162	)		-		-		(162	)
Total Liabilities	$	(536	)	$	-	$	-	$	(536	)

	Fair Value			Fair value measurement using
	December 31,
(in thousands)	2024			Level 1		Level 2		Level 3
Assets:
Money market funds	$	598		$	598	$	-	$	-
Total Assets	$	598		$	598	$	-	$	-
Liabilities:
Derivative liability - ELOC commitment note	$	(299	)	$	-	$	-	$	(299	)
Common stock warrant liability		(305	)		-		-		(305	)
Total Liabilities	$	(604	)	$	-	$	-	$	(604	)

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]

	Three Months Ended March 31, 2025
Balance at December 31, 2024	$	305
Change in fair value		(134	)
Settlement of common stock warrant liability		(9	)
Balance at March 31, 2025	$	162

	Three Months Ended March 31, 2025
Balance at December 31, 2024	$	299
Change in fair value		(188	)
Extinguishment of derivative		(111	)
Balance at March 31, 2025	$	-

Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]

	July 22, 2024 Issuance Date			July 29, 2024 Issuance Date			March 31, 2025			December 31, 2024
Fair value of underlying equity	$	3.56		$	3.29		$	1.26		$	0.35
Exercise price	$	4.11		$	4.11		$	1.10		$	1.28
Volatility		108.4	%		115.6	%		132.9	%		n/a
Risk-free interest rate		4.2	%		4.1	%		4.0	%		4.4	%
Expected term (in years)		5.5			5.5			4.8			5.1
Discounting factor		n/a			n/a			n/a			0.81

	June 26, 2024 Issuance Date			December 31, 2024
Fair value of underlying equity	$	3.22		0.3220.3535
Volatility		87.3%-91.7%			240.2%-252.0%
Risk-free interest rate		5.1	%		4.2	%
Conversion price discount		20.0	%		20.0	%
Discounting period (in years)		1.0			0.5
Discount rate		20.2	%		9.1	%
Discounting factor		0.83			0.96

Fair Value Measurements, Nonrecurring [Table Text Block]

	Fair Value		Fair value measurement using
	December 31,
(in thousands)	2024		Level 1		Level 2		Level 3
Intangible assets:
Rostafuroxin drug candidate	$	1,790	$	-	$	-	$	1,790